Transition Therapeutics is a biopharmaceutical company focused on the development of novel therapeutics for disease indications with large markets. The company’s lead product, ELND005, is a treatment for Alzheimer’s disease and bipolar disorder. Transition additionally has an emerging pipeline of innovative preclinical and clinical drug candidates that includes drugs for anti-inflammatory and metabolic indications. For more information, visit the company’s Web site at www.transitiontherapeutics.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: